PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Darbepoetin Alfa→

Darbepoetin Alfa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
209810-58-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Erythropoiesis-stimulating AgentErythropoietinIncreased Erythroid Cell Production
Mechanism of action
Aranesp stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.
Indications / reported uses
  • Anemia
  • anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis
  • anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Darbepoetin Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Darbepoetin Alfa Permitted Daily Exposure (PDE) report (the Darbepoetin Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Darbepoetin Alfa Occupational Exposure Limit (OEL) report (the Darbepoetin Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.